{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:32:08Z","timestamp":1786735928697,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Cancer"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/ijc.ijc_346_17","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T07:16:57Z","timestamp":1535008617000},"page":"94","source":"Crossref","is-referenced-by-count":11,"title":["Metronomic therapy in metastatic castrate-resistant prostate cancer: Experience from a tertiary cancer care center"],"prefix":"10.4103","volume":"55","author":[{"given":"Sandip","family":"Ganguly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Dabkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bivas","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joydeep","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-509X.239587-1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.mgene.2014.07.007","article-title":"Epidemiology of prostate cancer in India","author":"Jain","year":"2014","journal-title":"Meta Gene"},{"key":"key-10.4103\/0019-509X.239587-2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/ijc.27711","article-title":"Estimates of global cancer prevalence for 27 sites in the adult population in 2008","author":"Bray","year":"2013","journal-title":"Int J Cancer"},{"key":"key-10.4103\/0019-509X.239587-3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.239587-4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1053\/j.seminoncol.2013.04.015","article-title":"Chemotherapy and targeted therapies: Are we making progress in castrate-resistant prostate cancer?","author":"Hoffman-Censits","year":"2013","journal-title":"Semin Oncol"},{"key":"key-10.4103\/0019-509X.239587-5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11537480-000000000-00000","article-title":"Metronomic chemotherapy for metastatic prostate cancer: A 'young' concept for old patients?","author":"Fontana","year":"2010","journal-title":"Drugs Aging"},{"key":"key-10.4103\/0019-509X.239587-6","first-page":"1147","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","author":"de","year":"2010","journal-title":"Lancet"},{"key":"key-10.4103\/0019-509X.239587-7","first-page":"4317","article-title":"Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure","author":"Ladoire","year":"2010","journal-title":"Anticancer Res"},{"key":"key-10.4103\/0019-509X.239587-8","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/cncr.11713","article-title":"Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma","author":"Glode","year":"2003","journal-title":"Cancer"},{"key":"key-10.4103\/0019-509X.239587-9","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/bjc.2012.78","article-title":"Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate","author":"Dickinson","year":"2012","journal-title":"Br J Cancer"},{"key":"key-10.4103\/0019-509X.239587-10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/0976-500X.136098","article-title":"Metronomic chemotherapy","author":"Maiti","year":"2014","journal-title":"J Pharmacol Pharmacother","ISSN":"https:\/\/id.crossref.org\/issn\/0976-500X","issn-type":"print"},{"key":"key-10.4103\/0019-509X.239587-11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3747\/co.v16i2.420","article-title":"Metronomic chemotherapy: Changing the paradigm that more is better","author":"Scharovsky","year":"2009","journal-title":"Curr Oncol"},{"key":"key-10.4103\/0019-509X.239587-12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jcb.10772","article-title":"Angiogenesis and prostate cancer tumor growth","author":"Nicholson","year":"2004","journal-title":"J Cell Biochem"},{"key":"key-10.4103\/0019-509X.239587-13","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-03-3126","article-title":"Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression","author":"Hamano","year":"2004","journal-title":"Cancer Res"},{"key":"key-10.4103\/0019-509X.239587-14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"key-10.4103\/0019-509X.239587-15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000048411","article-title":"Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone","author":"Morioka","year":"2002","journal-title":"Urol Int"},{"key":"key-10.4103\/0019-509X.239587-16","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-05-2085","article-title":"Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells","author":"Yano","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:35:10Z","timestamp":1786732510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_346_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"alternative-id":["239587"],"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_346_17","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}